EZH2 links pancreatitis to tissue regeneration and pancreatic cancer

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue 4, 2012, Pages 323-324

  Lasfargues, Charline ^a   Pyronnet, Stéphane ^a  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR EZH2;

ANTITUMOR GENE; CANCER GROWTH; CANCER PREVENTION; CANCER PROGNOSIS; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL REGENERATION; ENZYME ACTIVITY; GENE FUNCTION; HUMAN; LOSS OF FUNCTION MUTATION; NOTE; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PANCREATITIS; TISSUE REGENERATION;

EID: 84865982589     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2012.05.010     Document Type: Article

References (3)

1. Mallen-St. Clair J., Soydaner-Azeloglu R., Lee K.E., Taylor L., Livanos A., Pylayeva-Gupta Y., et al. EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev 2012, 26:439-444.
2. Chang C.J., Hung M.C. The role of EZH2 in tumour progression. Br J Cancer 2012, 106:243-247.
3. Aguirre A.J., Bardeesy N., Sinha M., Lopez L., Tuveson D.A., Horner J., et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 2003, 17:3112-3126.